Satraplatin for hormone-refractory prostate cancer.

摘要

Satraplatin, which is currently awaiting approval by the US Food and Drug Adminstration, significantly decreased the risk for disease progression in a phase III trial in hormone-refractory prostate cancer (HRPC), according to a study presented at the 3rd Prostate Cancer Symposium (Orlando, FL, USA; Feb 22-24, 2007). 950 patients who had failed treatment with at least one previous regimen were randomised to receive prednisone plus satraplatin, or placebo. Patients treated with satraplatin had a 40% decrease in the risk of disease progression compared with those in the placebo group. The improvement in progression-free survival (PFS) increased over time. At the median time, PFS was 11 weeks and 10 weeks in the satraplatin and placebo groups, respectively. At the 75th percentile, PFS improved by 89% (36 vs 19 weeks). After 6 months, 30% of the satraplatin and 17% of the placebo group had not progressed; and at 12 months, nonprogression was 16% and 7%, respectively.